Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin
Status:
Completed
Trial end date:
2017-05-12
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the effects of rifampicin on the pharmacokinetics (PK) of sotagliflozin and its
metabolite in healthy male and female subjects.
Secondary Objectives:
- To assess total 24-hour urinary glucose excretion (UGE) after a dose of sotagliflozin
400 mg, alone and with rifampicin, in healthy male and female subjects.
- To assess the safety and tolerability of single dose sotagliflozin with and without
rifampicin in healthy male and female subjects.